Клиническое значение β-адреноблокады при артериальной гипертензии на примере небиволола (реферат)
Клиническое значение β-адреноблокады при артериальной гипертензии на примере небиволола (реферат)
Н.А.Ваулин. Клиническое значение
β-адреноблокады при артериальной гипертензии на примере небиволола (реферат).
Справочник поликлинического врача. 2010;
8: 19–24.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Julius S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens 1996; 9: 113S–120S.
2. Narkiewicz K, Grassi G, Mancia G, Hedner T. The sympathetic nervous system and cardiovascular disease. Via Medica, Gdansk 2008.
3. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues andclinical applications. Eur Heart J 2006; 27: 2588–605.
4. Laurent S, Boutouyrie P. Recent advances in arterial stiffness andwave reflection in human hypertension. Hypertension 2007; 49: 1202–6.
5. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004; 44: 112–6.
6. UK National Institute for Health and Clinical Excellence and British Hypertension Society. Hypertension: management of hypertension in adults in primary care. 2006; www.nice.org.uk/CG034
7. Lindholm LH, Carlberg B, Samuelsson B. Should beta-blockers remain first choice in the treatment of primary hypertension. A meta-analysis. Lancet 2005; 366:1545–53.
8. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 2008; 336: 1121–3.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25: 1105–1187.
10. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J Suppl 2009; 11 (Suppl. A): A3–A8.
11. Agabiti RE, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67: 1097–107.
12. Cockcroft R, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidencefor an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067–71.
13. Cockcroft J. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag 2007; 3: 909–17.
14. Van Bortel LM, Fici F, Mascagni E. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 8: 35–44.
15. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.
16. F Pasini A, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23 (3): 589–96.
17. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–6.
18. Fogari R, Zoppi A, Lazzari P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity. Cardiovasc Drugs Ther 1992; 6: 239–47.
19. Makolkin VI, Akhmedova OO, Buval'tsev VI et al. Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and heart disease associated with type 2 diabetes. Kardiologiia 2003; 43 (2): 40–3.
20. McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305–10.
21. Dhakam Z, Yasmin, McEniery CM et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351–6.
2. Narkiewicz K, Grassi G, Mancia G, Hedner T. The sympathetic nervous system and cardiovascular disease. Via Medica, Gdansk 2008.
3. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues andclinical applications. Eur Heart J 2006; 27: 2588–605.
4. Laurent S, Boutouyrie P. Recent advances in arterial stiffness andwave reflection in human hypertension. Hypertension 2007; 49: 1202–6.
5. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004; 44: 112–6.
6. UK National Institute for Health and Clinical Excellence and British Hypertension Society. Hypertension: management of hypertension in adults in primary care. 2006; www.nice.org.uk/CG034
7. Lindholm LH, Carlberg B, Samuelsson B. Should beta-blockers remain first choice in the treatment of primary hypertension. A meta-analysis. Lancet 2005; 366:1545–53.
8. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 2008; 336: 1121–3.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25: 1105–1187.
10. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J Suppl 2009; 11 (Suppl. A): A3–A8.
11. Agabiti RE, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67: 1097–107.
12. Cockcroft R, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidencefor an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067–71.
13. Cockcroft J. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag 2007; 3: 909–17.
14. Van Bortel LM, Fici F, Mascagni E. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 8: 35–44.
15. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.
16. F Pasini A, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23 (3): 589–96.
17. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–6.
18. Fogari R, Zoppi A, Lazzari P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity. Cardiovasc Drugs Ther 1992; 6: 239–47.
19. Makolkin VI, Akhmedova OO, Buval'tsev VI et al. Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and heart disease associated with type 2 diabetes. Kardiologiia 2003; 43 (2): 40–3.
20. McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305–10.
21. Dhakam Z, Yasmin, McEniery CM et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351–6.
Авторы
Н.А.Ваулин
Городская клиническая больница №29, Москва
Городская клиническая больница №29, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.